Advertisement

Pharmaceutical Research

, Volume 21, Issue 11, pp 2064–2071 | Cite as

Pharmacokinetics of Teicoplanin in An ICU Population of Children and Infants

  • John C Lukas
  • Georgios Karikas
  • Maria Gazouli
  • Panagiotis Kalabalikis
  • Tasos Hatzis
  • Panos Macheras
Article

Abstract

Purpose. Better dosing is needed for antibiotics, including teicoplanin (TEI), to prevent emergence of resistant bacterial strains. Here, we assess the TEI pharmacokinetics (PK) related to a 10 mg/l minimum inhibitory concentration (MIC) target in ICU children (4 to 120 months; n = 20) with gram+ infections.

Methods. Standard administration of TEI was with three 10 mg/kg Q12h, loading infusions, and maintainance with 10 mg/kg or 15 mg/kg Q24h. During maintenance, 9 samples (3/day) were collected per patient and the PK analyzed with Nonlinear Mixed Effects Model (NONMEM).

Results. Thirty-five percent of concentrations in older children (≥2 months) vs. 8% in younger infants (<12 months) were below the target MIC. The global bicompartmental population PK parameters were [mean (interindividual CV%)] CL = 0.23 l/h [72%], V = 3.16 l [58%], k12 = 0.23 h−1, and k21 = 0.04 h−1. Two PK subpopulations were identified. The older children had CL = 0.29 [23%] l/h, V = 3.9 l and the younger infants, CL = 0.09 [37%] l/h, V = 1.05 l. Residual error was reduced from 52% to around 30% in the final models.

Conclusions. Older children in the ICU may require relatively higher doses of teicoplanin. However, a study in a larger population is needed.

children infants NONMEM pharmacokinetics simulation teicoplanin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    H. Wisplinghoff, H. Seifert, S. M. Tallent, T. Bischoff, R. P. Wenzel, and M. B. Edmond. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22:686–691 (2003).PubMedGoogle Scholar
  2. 2.
    H. M. Aucken, M. Ganner, S. Murchan, B. D. Cookson, and A. P. Johnson. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J. Antimic. Chemother. 50:171–175 (2002).Google Scholar
  3. 3.
    A. P. Johnson, C. Henwood, S. Mushtaq, D. James, M. Warner, and D. M. Livermore. ICU Study Group. Susceptibility of gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J. Hosp. Infect. 54:179–187 (2003).PubMedGoogle Scholar
  4. 4.
    J. Cepeda, S. Hayman, T. Whitehouse, C. C. Kibbler, D. Liver-more, M. Singer, and A. P. Wilson. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J. Antimicrob. Chemother. 52:533–534 (2003).PubMedGoogle Scholar
  5. 5.
    J. M. Hamilton-Miller. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infecion 30:118–124 (2002).Google Scholar
  6. 6.
    G. L. Drusano. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 15((Suppl 1)):42–50 (2003).Google Scholar
  7. 7.
    G. L. Traina and M. Bonati. Pharmacokinetics of teicoplanin in man after intravenous administration. J. Pharmacokinet. Biopharm. 12:119–128 (1984).PubMedGoogle Scholar
  8. 8.
    J. D. Knudsen, K. Fuursted, S. Raber, F. Espersen, and N. Frimodt Moller. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother. 44:1247–1254 (2000).PubMedGoogle Scholar
  9. 9.
    P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible methicillin-resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother. 47:163–170 (2001).PubMedGoogle Scholar
  10. 10.
    M. Rowland. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 18:184–209 (1990).PubMedGoogle Scholar
  11. 11.
    A. P. Wilson. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 39:167–183 (2000).PubMedGoogle Scholar
  12. 12.
    V. Fanos, M. Mussap, B. J. Khoory, S. Vecchini, M. Plebani, and D. Benini. Renal tolerability of teicoplanin in a case of neonatal overdose. J. Chemother. 10:381–384 (1998).PubMedGoogle Scholar
  13. 13.
    A. Louie, P. Kaw, W. Liu, N. Jumpe, M. H. Miller, and G. L. Drusano. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845–851 (2001).PubMedGoogle Scholar
  14. 14.
    N. Jauregizar, J. A. Wald, A. Astobieta, J. M. Rodriguez Sasiain, J. C. Lucas, and R. Calvo. Population pharmacokinetics of netilmicin in short term prophylactic treatment. Br. J. Clin. Pharmacol. 55:552–559 (2003).PubMedGoogle Scholar
  15. 15.
    A. Sanchez, J. Lopez-Herce, E. Cueto, A. Camllo, and R. Moral. Teicoplanin pharmacokinetics in critically ill paediatric patients. J. Antimicrob. Chemother. 44:407–409 (1999).PubMedGoogle Scholar
  16. 16.
    D. R. Butler, R. J. Kuhn, and M. H. Chandler. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet. 26:374–395 (1994).PubMedGoogle Scholar
  17. 17.
    R. F. Reinoso, B. A. Telfer, B. S. Brennan, and M. Rowland. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab. Dispos. 29:453–459 (2001).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • John C Lukas
    • 1
    • 2
  • Georgios Karikas
    • 3
  • Maria Gazouli
    • 4
  • Panagiotis Kalabalikis
    • 3
  • Tasos Hatzis
    • 3
  • Panos Macheras
    • 1
  1. 1.Laboratory of Biopharmaceutics and Pharmacokinetics, School of PharmacyUniversity of Athens, ZografouAthensGreece
  2. 2.Department of Pharmacy and Pharmaceutical TechnologyUniversity of SalamancaSalamancaSpain
  3. 3.Pediatric Intensive Care Unit and Parenteral Nutrition and Pharmacokinetics Unit, “Aghia Sofia” Children's HospitalAthensGreece
  4. 4.Department of Histology and Embryology, School of MedicineUniversity of AthensAthensGreece

Personalised recommendations